

## **Dynamics of prescription drug use, diagnoses and health care utilization after community managed SARS-CoV-2 infection**

### **Conflicts of interest:**

Anton Pottegård and Jesper Hallas report participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the current proposal. Lars Christian Lund reports participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the current proposal. Henrik Nielsen reports participation in research projects funded by MSD and Novo Nordisk Foundation, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the current proposal. Christian Fynbo Christiansen and Reimar Wernich Thomsen have not received any personal fees, grants, travel grants, or teaching grants from companies, but the Department of Clinical Epidemiology is involved in studies with funding from various companies as research grants to (and administered by) Aarhus University. None of these studies are related to the current study. Anders Koch, Stine Hasling Mogensen and Nikolai Constantin Brun report no conflicts of interest.